These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 17651931)
21. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation. Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559 [TBL] [Abstract][Full Text] [Related]
22. Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Castelli F; Sarpietro MG; Ceruti M; Rocco F; Cattel L Mol Pharm; 2006; 3(6):737-44. PubMed ID: 17140261 [TBL] [Abstract][Full Text] [Related]
23. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives. Peters GJ; Voorn DA; Kuiper CM; van der Wilt CL; Noordhuis P; Smid K; Myhren F; Sandvold M; Hendriks HR Nucleosides Nucleotides; 1999; 18(4-5):877-8. PubMed ID: 10432699 [TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery. Xu S; Xu Q; Zhou J; Wang J; Zhang N; Zhang L J Nanosci Nanotechnol; 2013 Jan; 13(1):129-38. PubMed ID: 23646707 [TBL] [Abstract][Full Text] [Related]
25. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740 [TBL] [Abstract][Full Text] [Related]
26. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150 [TBL] [Abstract][Full Text] [Related]
27. Combination of l-Carnitine with Lipophilic Linkage-Donating Gemcitabine Derivatives as Intestinal Novel Organic Cation Transporter 2-Targeting Oral Prodrugs. Wang G; Chen H; Zhao D; Ding D; Sun M; Kou L; Luo C; Zhang D; Yi X; Dong J; Wang J; Liu X; He Z; Sun J J Med Chem; 2017 Mar; 60(6):2552-2561. PubMed ID: 28234466 [TBL] [Abstract][Full Text] [Related]
28. Tailoring the properties of mPEG-PLLA nanoparticles for better encapsulation and tuned release of the hydrophilic anticancer drug. Surwase SS; Munot NM; Idage BB; Idage SB Drug Deliv Transl Res; 2017 Jun; 7(3):416-427. PubMed ID: 28324320 [TBL] [Abstract][Full Text] [Related]
29. An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug:a comparative study. Gupta A; Asthana S; Konwar R; Chourasia MK J Biomed Nanotechnol; 2013 May; 9(5):915-25. PubMed ID: 23802424 [TBL] [Abstract][Full Text] [Related]
30. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806 [TBL] [Abstract][Full Text] [Related]
31. N-Acyl-phosphoramidates as potential novel form of gemcitabine prodrugs. Baraniak J; Pietkiewicz A; Kaczmarek R; Radzikowska E; Kulik K; Krolewska K; Cieslak M; Krakowiak A; Nawrot B Bioorg Med Chem; 2014 Apr; 22(7):2133-40. PubMed ID: 24631359 [TBL] [Abstract][Full Text] [Related]
32. Characterization of Gemcitabine Loaded Polyhydroxybutyrate Coated Magnetic Nanoparticles for Targeted Drug Delivery. Parsian M; Mutlu P; Yalcin S; Gunduz U Anticancer Agents Med Chem; 2020; 20(10):1233-1240. PubMed ID: 32156242 [TBL] [Abstract][Full Text] [Related]
33. Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives. Federico C; Morittu VM; Britti D; Trapasso E; Cosco D Int J Nanomedicine; 2012; 7():5423-36. PubMed ID: 23139626 [TBL] [Abstract][Full Text] [Related]
34. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Hung SW; Marrache S; Cummins S; Bhutia YD; Mody H; Hooks SB; Dhar S; Govindarajan R Cancer Lett; 2015 Apr; 359(2):233-40. PubMed ID: 25600708 [TBL] [Abstract][Full Text] [Related]
35. Cell-specific activation of gemcitabine by endogenous H Maiti M; Yoon SA; Cha Y; Athul KK; Bhuniya S; Lee MH Chem Commun (Camb); 2021 Sep; 57(75):9614-9617. PubMed ID: 34486009 [TBL] [Abstract][Full Text] [Related]
37. Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro. Li JM; Chen W; Wang H; Jin C; Yu XJ; Lu WY; Cui L; Fu DL; Ni QX; Hou HM Acta Pharmacol Sin; 2009 Sep; 30(9):1337-43. PubMed ID: 19730429 [TBL] [Abstract][Full Text] [Related]